Tango Therapeutics, Inc.
TNGX
Classement en actions
#4542
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Prix de l'action
$27.18
Dernière synchronisation: 2026-07-31
Capitalisation boursière
$3.38B
Changement (1 jour)
-1.41%
Changement (1 an)
202.34%
Pays
US
Échange Tango Therapeutics, Inc. (TNGX)
Catégorie
Healthcare
Revenus pour Tango Therapeutics, Inc. (TNGX)
Revenus en Jun 2026 TTM : $53.81M
Selon les derniers rapports financiers de Tango Therapeutics, Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de $53.81M. En 2023, l'entreprise a réalisé un chiffre d'affaires de $36.53M une augmentation par rapport à le chiffre d'affaires de l'année 2022, qui était de $24.86M. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Tango Therapeutics, Inc. de 2019 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2026 (TTM) | $53.81M | 27.91% |
| 2024 | $42.07M | 15.17% |
| 2023 | $36.53M | 46.93% |
| 2022 | $24.86M | -32.89% |
| 2021 | $37.04M | 383.83% |
| 2020 | $7.66M | -68.94% |
| 2019 | $24.65M | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $12.62B | 23,360.44% |
US
|
|
| $2.23B | 4,040.42% |
US
|
|
| $15.74B | 29,158.57% |
AU
|
|
| $6.02B | 11,089.70% |
NL
|
|
| - | - |
CH
|
